Curis (CRIS) Research & Development (2010 - 2026)
Curis' (CRIS) quarterly Research & Development came in at $6.4 million in Q1 2026, down 24.48% YoY from $8.5 million in Q1 2025, and up 10.71% on a QoQ basis from $5.8 million in Q4 2025.
Curis (CRIS) Research & Development (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Research & Development data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Research & Development fell 24.48% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 30.2% YoY) and the FY2025 annual result came in at $28.3 million, down 26.73% from the prior year.
- Research & Development advanced to $6.4 million in Q1 2026, from $5.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $12.3 million in Q2 2022 to a low of $5.8 million in Q4 2025.
- A 5-year average of $9.2 million and a median of $9.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 69.23% — and 2025, when it tumbled 35.05%.
- Tracing CRIS's Research & Development over 5 years: stood at $8.7 million in 2022, then rose by 14.45% to $10.0 million in 2023, then slipped by 10.0% to $9.0 million in 2024, then plunged by 35.05% to $5.8 million in 2025, then rose by 10.71% to $6.4 million in 2026.
- The last three Research & Development figures came in at $6.4 million (Q1 2026), $5.8 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | Curis | 3.32 Mn | -2.30 Mn | - | 6.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.45 Mn |
| Dec 31, 2025 | 5.83 Mn |
| Sep 30, 2025 | 6.43 Mn |
| Jun 30, 2025 | 7.46 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | 8.97 Mn |
| Sep 30, 2024 | 9.72 Mn |
| Jun 30, 2024 | 10.25 Mn |
| Mar 31, 2024 | 9.62 Mn |
| Dec 31, 2023 | 9.96 Mn |
| Sep 30, 2023 | 10.38 Mn |
| Jun 30, 2023 | 10.01 Mn |
| Mar 31, 2023 | 9.14 Mn |
| Dec 31, 2022 | 8.71 Mn |
| Sep 30, 2022 | 10.81 Mn |
| Jun 30, 2022 | 12.32 Mn |
| Mar 31, 2022 | 11.44 Mn |
| Dec 31, 2021 | 10.77 Mn |
| Sep 30, 2021 | 8.60 Mn |
| Jun 30, 2021 | 8.75 Mn |